Big Pharma just rewrote the rulebook in the obesity-treatment race. Pfizer has won the bidding for Metsera after a showdown with Novo Nordisk.
Dan Koh and Emaad Akhtar unpack how this US$10 billion move signals a pivot into GLP-1 drugs, why Novo walked away and what it all means for investors tracking the next trillion-dollar health-tech frontier.

Breakfast Quiz: How good is your general knowledge of the Middle East?
05:22

Budget 2026 Roundtable: A month in, what’s actually changing?
10:29

Morning Shot: Are Tuition Centres Overselling Success?
12:21